Svirbely J E, Pesce A J, Singh S, O'Flaherty E J
Department of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, Ohio.
Clin Pharmacokinet. 1989 May;16(5):317-25. doi: 10.2165/00003088-198916050-00004.
The pharmacokinetics of co-trimoxazole (sulphamethoxazole plus trimethoprim) were studied in end-stage renal disease in patients undergoing treatment with continuous ambulatory peritoneal dialysis (CAPD) and free of peritonitis. Plasma and dialysate concentrations were monitored for 1 exchange after administration of a single oral or intraperitoneal dose of co-trimoxazole, and were fitted by a pharmacokinetic model that took into account the equilibrium nature of CAPD by including return from the peritoneum in oral studies and from the plasma in intraperitoneal studies. Clearances were calculated and compared by analysis of variance. There was a significant effect of direction of flow (p less than 0.01), plasma-peritoneal clearances being larger than peritoneal-plasma clearances for both drugs. In addition, there was a significant difference (p less than 0.0001) between sulphamethoxazole clearances and trimethoprim clearances, with the latter being greater in both directions.
在接受持续非卧床腹膜透析（CAPD）且无腹膜炎的终末期肾病患者中研究了复方新诺明（磺胺甲恶唑加甲氧苄啶）的药代动力学。在单次口服或腹腔内给予复方新诺明后，监测1次交换的血浆和透析液浓度，并通过药代动力学模型进行拟合，该模型通过在口服研究中纳入来自腹膜的回吸收以及在腹腔内研究中纳入来自血浆的回吸收来考虑CAPD的平衡性质。通过方差分析计算并比较清除率。流动方向有显著影响（p小于0.01），两种药物的血浆 - 腹膜清除率均大于腹膜 - 血浆清除率。此外，磺胺甲恶唑清除率和甲氧苄啶清除率之间存在显著差异（p小于0.0001），后者在两个方向上均更高。
